Ovarian Cancer Clinical Trial
A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3. This study consists of 4 cohorts in participants with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. Each cohort will test a combination of ZN-c3 with either pegylated liposomal doxorubicin (PLD), carboplatin, paclitaxel, or gemcitabine.
Provision of written informed consent prior to initiation of any study-related procedures that are not considered standard of care.
Females ≥ 18 years of age or the minimum legal adult age (whichever is greater) at the time of informed consent.
ECOG performance status ≤ 2.
Histologically or cytologically confirmed high-grade serous epithelial ovarian carcinoma, fallopian tube, or peritoneal carcinoma.
Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy in the advanced or metastatic setting.
The disease must be platinum-resistant, i.e., the Platinum-Free Interval (PFI) must have been < 6 months. Platinum refractory disease, i.e., PD during first-line platinum-based therapy is allowed.
Measurable disease per RECIST version 1.1.
Adequate hematologic and organ function as defined by the following criteria:
ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily administration of filgrastim/sargramostim or within 3 weeks after administration of pegfilgrastim.
Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days after transfusion of platelets or within 3 weeks after administration of platelet growth factors.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastases, AST and ALT ≤ 5 x ULN.
Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.
Female subjects of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-hCG) test and agree to use an effective method of contraception per institutional standard.
Left ventricular ejection fraction (LVEF) ≥ 50% or within normal limits of the institution (only for subjects treated with PLD).
Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor.
Any of the following treatment interventions within the specified time frame prior to Cycle 1 Day 1:
Major surgery within 28 days.
Radiation therapy within 21 days.
Autologous or allogeneic stem cell transplant within 3 months.
Inability to discontinue treatment for 5 half-lives or 14 days (whichever is longer) prior to Cycle 1 Day 1 with prescription or non-prescription drugs, or to discontinue consumption of food and herbal supplements, that are:
strong and moderate CYP3A inhibitors
strong and moderate CYP3A inducers
A serious illness or medical condition(s) including, but not limited to, the following:
Brain metastases that require immediate treatment or are clinically or radiographically unstable.
Leptomeningeal disease that requires or is anticipated to require immediate treatment.
Myocardial impairment of any cause.
Significant gastrointestinal abnormalities.
Active or uncontrolled infection.
Any evidence of small bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, recent hospitalization for small bowel obstruction within 3 months prior to Cycle 1 Day 1, or recurrent paracentesis or thoracentesis within 6 weeks prior to Cycle 1 Day 1.
Unresolved toxicity of Grade > 1 attributed to any prior therapies (excluding Grade 2 neuropathy, alopecia or skin pigmentation).
Pregnant or lactating females (including the cessation of lactation) or females of childbearing potential who have a positive serum pregnancy test within 14 days prior to Cycle 1 Day 1.
Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of > 480 msec, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
History or current evidence of congenital long QT syndrome.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 21 Locations for this study
Aurora Colorado, 80045, United States
Boston Massachusetts, 02215, United States
Saint Louis Missouri, 53110, United States
New York New York, 10029, United States
Durham North Carolina, 27710, United States
Providence Rhode Island, 02905, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
South Brisbane Queensland, 4101, Australia
Sunshine Coast Queensland, 4556, Australia
Melbourne Victoria, 3144, Australia
Nedlands Western Australia, 6009, Australia
Banja Luka , 78000, Bosnia and Herzegovina
Sarajevo , 71000, Bosnia and Herzegovina
Tuzla , 75000, Bosnia and Herzegovina
Panagyurishte , 4500, Bulgaria
Sofia , 1632, Bulgaria
Tbilisi , 0112, Georgia
Busan , , Korea, Republic of
Seoul , 03080, Korea, Republic of
Seoul , 05505, Korea, Republic of
Belgrade , 11080, Serbia
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.